ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Japan's Shionogi seeks OK for COVID-19 pill in South Korea via tie-up

Emergency use authorization has been delayed in home market

Shinogi aims for early authorization of the antiviral drug in South Korea after a setback in Japan. (Photos by Shionogi, Tomoki Mera)

OSAKA -- Japanese drugmaker Shionogi will work with a company in South Korea to seek authorization there for a treatment for COVID-19 under an agreement announced Friday.

As part of the deal, Seoul-headquartered Ildong Pharmaceutical will be responsible for applying for emergency use authorization for the COVID-19 pill and, if the application is approved, for negotiating government purchases.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more